Su Zhang
Education
Ph.D. and M.A., economics, Duke University; B.A., economics, Huazhong University of Science and Technology
Summary of Experience
Dr. Zhang is a health economist with expertise in health economics and outcomes research (HEOR) who has worked on a variety of projects for pharmaceutical companies. He has experience with analyses related to treatment patterns, disease burden, cost calculation, comparative effectiveness, insurance claims, electronic medical records, chart reviews, surveys, cost effectiveness, and literature reviews. Dr. Zhang’s work spans disease areas such as oncology, hematology, dermatology, rheumatology, endocrinology, neurology, and pulmonology. His research has been presented at numerous international clinical conferences and published in several peer-reviewed journals.
-
Real-World Neoadjuvant Treatment Patterns and Outcomes in Resected Non-Small-Cell Lung Cancer
Clinical Lung Cancer, 2024
2024Donington J, Hu X, Zhang S, Song Y, Arunachalam A, Chirovsky D, Gao C, Lerner A, Jiang A, Signorovitch J, Samkari A
-
Disease-Free Survival as a Predictor of Overall Survival in Localized Renal Cell Carcinoma Following Initial Nephrectomy: A Retrospective Analysis of Surveillance, Epidemiology and End Results-Medicare Data
International Journal of Urology, 2023
2023Haas NB, Song Y, Rogerio JW, Zhang S, Carley C, Zhu J, Bhattacharya R, Signorovitch J, Sundaram M
-
Evaluation of Disease-Free Survival as a Predictor of Overall Survival and Assessment of Real-World Burden of Disease Recurrence in Resected Early-Stage Non-Small Cell Lung Cancer
Journal of Managed Care & Specialty Pharmacy, 2023
2023West H, Hu X, Zhang S, Song Y, Chirovsky D, Gao C, Lerner A, Jiang A, Signorovitch J, Samkari A
-
Treatment Patterns and Outcomes in Resected Early-Stage Non-Small Cell Lung Cancer: An Analysis of the Seer-Medicare Data
Clinical Lung Cancer, 2023
2023West H, Hu X, Zhang S, Song Y, Chirovsky D, Gao C, Lerner A, Jiang A, Signorovitch J, Samkari A
-
Event-Free Survival as a Predictor of Overall Survival and Recurrence Burden of Patients with Non-Small Cell Lung Cancer Receiving Neoadjuvant Therapy
The Journal of Thoracic and Cardiovascular Surgery, 2023
2023Donington J, Hu X, Zhang S, Song Y, Arunachalam A, Chirovsky D, Gao C, Lerner A, Jiang A, Signorovitch J, Samkari A
-
Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: A retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data
Journal of Managed Care & Specialty Pharmacy, 2022
2022Sundaram M, Song Y, Rogerio JW, Zhang S, Bhattacharya R, Adejoro O, Carley C, Zhu J, Signorovitch J, Haas NB
-
Real-World Adherence to Tetrabenazine or Deutetrabenazine Among Patients With Huntington's Disease: A Retrospective Database Analysis
Neurology and Therapy, 2022
2022Claassen DO, Ayyagari R, Garcia-Horton V, Zhang S, Alexander J, Leo S
-
Systematic Literature Review of Clinical and Economic Evidence for Spinal Muscular Atrophy
Advances in Therapy, 2021
2021Yang M, Awano H, Tanaka S, Toro W, Zhang S, Dabbous O, Igarashi A
-
-
Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States
Gynecologic Oncology, 2020
2020Muston D, Hettle R, Monberg M, McLaurin KK, Gao W, Swallow E, Zhang S, Kalemaj I, Signorovitch J, Moore K
-
A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer
Pharmacoeconomics, 2020
2020Gao W, Muston D, Monberg M, McLaurin K, Hettle R, Szamreta E, Swallow E, Zhang S, Kalemaj I, Signorovitch J, McQueen RB